Drug
Sage 217
Sage 217: highest development phase Phase 3, developed by Biogen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| SAGE-217 NCT03771664 | Phase 3 | Major Depressive Disorder |
Latest
No recent events.
Follow Sage 217 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.